Lawrence Helson received his BS from City College of New York, MS fron New York University, and a B.Med Sci and MD from the University of Geneva (Switzerland). Dr. Helson has served as Professor of Oncology at New York Medical College, Cornell University Medical School, and Attending Physician at Memorial Sloan Kettering Cancer Center (MSKCC). While at MSKCC he established a number of human tumor cell lines, including SK-N-SH which is an in vitro dopaminergic model for Parkinson's disease studies.

His pharmaceutical industrial experience includes positions as Trial Director at Imperial Chemical Industries, Delaware, and Director at Napro Biotherapeutics, Onconova, Inc. He is currently CEO and President of Sign Path Pharma Inc.

Dr. Helson is a fellow of the American Academy of Pediatrics. He has published about185 papers in peer-reviewed journals, and is the holder of five patents.